| Exclusion Criteria: | Any co-morbid condition that renders the subject at high risk of greatment complication or reduces the probability of assessing clinical effect.
Received cytotoxic chemotherapy, biological therapy (including hormonotherapy), radiation therapy or immunosuppressants within 3 weeks prior to Day 1, Cycle 1 or who exhibit persistent clinical efidence of toxicity.
Received monoclonal antibodies (eg rituximab) within 8 weeks prior to Day 1, Cycle 1.
Received investigational agents within 4 weeks prior to Day 1, Cycle 1.
Received radioimmunotherapy or nitrosourea within 8 weeks prior to Day 1, Cycle 1 or who exhibit persistent clinical evidence of toxicity.
The use of corticosteroids within 1 week prior to Day 1, Cycle 1 (except at recommended maintenance doses for co-morbid conditions).
Subjects who are eligible for a hematopoietic stem cell transplant or who have had an autologous HSCT within the past 16 weeks.
Subjects with a prior history of an allogeneic HSCT.
Human immunodeficiency virus (HIV) infection, acquired immunodeficiency syndrome (AIDS)-related lymphoma, or central nervous system (CNS) lymphoma (primary or metastatic).
Grade 2 or greater neuropathy, graded by the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE).
Chronic or acute viral hepatitis.
Active infection requiring intravenous or oral antibiotics, or history of opportunistic infections within 4 weeks prior to Day 1, Cycle 1.
History of other cancers within 5 years of Day 1, Cycle 1 except for basal cell carcinoma of the skin and in situ cancers of the cervix.
Myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) within the last 6 months.
Major surgical procedure or significant traumatic injury within 4 weeks prior to day 1, cycle 1.
Pregnant or breast-feeding women. Women with an intact uterus (unless amenorrheic for the last 24 months) must have a negative serum pregnancy test at screening. All non-sterile, nonmenopausal females must agree to use medically approved method of contraception during the study and for 60 days following the last dose.
Males who do not agree to use effective contraception during the study and for a period of 60 days following the last dose of TRM-1.
|